1. Updates Abound

3. Introduction GLP-1 RAs in Combination With Basal Insulin Approved by US FDA

4. Why Combine a GLP-1 RA With Basal Insulin?

5. Adding Prandial Insulin to Basal Insulin

6. Exenatide Once Weekly Now Approved for Use With Basal Insulin

7. Exenatide QW + Insulin Reduced HbA1c and Body Weight Compared With Placebo + Insulin

8. Uptitration of Basal Insulin Dose or Intensification for Prandial Control

9. AACE/ACE Recommendations for Adding/Intensifying Insulin

10. Patient Satisfaction With GLP-1 RAs

11. Introduction: SGLT2 Inhibitors in Combination With Basal Insulin

12. DURATION-8 Combining Exenatide QW and Dapagliflozin vs Exenatide or Dapagliflozin in Patients With T2D on Metformin

13. DURATION-8 Change in HbA1c

14. Practicality in Clinical Practice

15. GLP-1 RA in Combination With an SGLT2 Inhibitor

16. New Data From DURATION-8 Presented at ADA 2018 Scientific Sessions

17. Weight, SBP, and Safety

18. The Increasing Role of GLP-1 RAs and SGLT2 Inhibitors for T2D

19. Concluding Remarks

20. Abbreviations

21. Abbreviations (cont)